Effect of high-dose atorvastatin on hospitalizations for heart failure - Subgroup analysis of the treating to new targets (TNT) study

Article; Proceedings Paper

关键词: A REDUCTASE INHIBITOR;    MYOCARDIAL-INFARCTION;    CHOLESTEROL LEVELS;    STATIN THERAPY;    TRIAL;    PRAVASTATIN;    CARDIOMYOPATHY;    ROSUVASTATIN;    INFLAMMATION;    DISEASE;   

DOI  :  10.1161/CIRCULATIONAHA.106.625574

来源: SCIE

【 摘 要 】

Background - Statins reduce the rate of major cardiovascular events in high-risk patients, but their potential benefit as treatment for heart failure ( HF) is less clear. Methods and Results - Patients (n=10 001) with stable coronary disease were randomized to treatment with atorvastatin 80 or 10 mg/d and followed up for a median of 4.9 years. A history of HF was present in 7.8% of patients. A known ejection fraction < 30% and advanced HF were exclusion criteria for the study. A predefined secondary end point of the study was hospitalization for HF. The incidence of hospitalization for HF was 2.4% in the 80-mg arm and 3.3% in the 10-mg arm (hazard ratio, 0.74; 95% confidence interval, 0.59 to 0.94; P=0.0116). The treatment effect of the higher dose was more marked in patients with a history of HF: 17.3% versus 10.6% in the 10- and 80-mg arms, respectively (hazard ratio, 0.59; 95% confidence interval, 0.4 to 0.88; P=0.009). Among patients without a history of HF, the rates of hospitalization for HF were much lower: 1.8% in the 80-mg group and 2.0% in the 10-mg group (hazard ratio, 0.87; 95% confidence interval, 0.64 to 1.16; P=0.34). Only one third of patients hospitalized for HF had evidence of preceding angina or myocardial infarction during the study period. Blood pressure was almost identical during follow-up in the treatment groups. Conclusions - Compared with a lower dose, intensive treatment with atorvastatin in patients with stable coronary disease significantly reduces hospitalizations for HF. In a post hoc analysis, this benefit was observed only in patients with a history of HF. The mechanism accounting for this benefit is unlikely to be due primarily to a reduction in interim coronary events or differences in blood pressure.

【 授权许可】

Free